Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Find a Broker »
- li>
- li>
- li>
- li>
- li>
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.24 | 1.29 | -3.73 |
| EPS, GAAP | 1.22 | 1.22 | 1.22 |
| Consensus Estimate | 1.46 | 1.49 | -2.29 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 5.71 | 5.30 | 7.85 |
| EPS, GAAP | 5.76 | 5.04 | 14.31 |
| Consensus Estimate | 6.56 | 5.88 | 11.40 |
| BIIB | Industry Average | |
| P/E (TTM) | 33.40 | NA |
| P/E (Forward) | 25.09 | NA |
| PEG Ratio | 1.37 | 2.19 |
| Price/Sales | 8.49 | 18.50 |
| Beta | 0.74 | 0.70 |
| 3:12 PM | 3/29/2013 | UPDATE: Biogen Prices Multiple-Sclerosis Drug Below Rivals |
| 1:14 PM | 3/29/2013 | Biogen Idec Prices MS Drug at a Discount |
| 4/3/2013 | Drug Firms Expand Powers to Recoup Pay (WSJ.com) |
| 4/3/2013 | Vanguard Reopens Capital Opportunity Fund --- That's a Contrarian Opportunity (Barrons.com) |
| 4/1/2013 | Charting the Market (Barrons.com) |
| 3/29/2013 | The Big Bull Market Road Map for April (24/7 Wall St) |
| 3/28/2013 | 24/7 Wall St. Closing Bell — March 28, 2013: Markets Higher, S&P 500 Sets Record (NKE, BIIB, RYAAY, VHS, LULU, XONE, PAYX, SNX, TXI, END, FINL, GME, MOS, BBRY, WGO, CALM, DQ, PF, MTG, S, CLWR, DISH) (24/7 Wall St) |
| 3/28/2013 | Biogen Idec Leads S&P After FDA Nod (Barrons.com) |
| 3/28/2013 | Top 12 Analyst Upgrades and Downgrades (ASTM, ARIA, BIIB, LULU, NKE, RYAAY, UA, UTX, VHS, VFC, MS, GS) (24/7 Wall St) |
| 3/27/2013 | FDA Approves Biogen Pill for Multiple Sclerosis (WSJ.com) |